StockData

Novavax vs Valneva

NVAX and VALN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NVAX and VALN compare

Valneva grew revenue faster over the last twelve months (−27.2% versus −61.6% for Novavax).

Novavax scores higher on the StockData Score (4 against 1 for Valneva), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNVAXVALN
Size and price
Market cap$1.3B–
Share price$8.06$5.65
Change, 1 year14.2%−38.8%
Change, 5 years−96.3%−90.5%
Beta (5Y)1.701.58
Employees749140
StockData Score
Total score4 (better)1
Valuation score1 (better)0
Growth score1 (better)0
Performance score1 (better)0
Health score11
Dividend score00
Valuation
P/S3.2×–
Growth
Revenue growth (TTM)−61.6%−27.2% (better)
Revenue growth, 5Y average18.8% (better)9.6%
Net income growth (TTM)−159%–
EPS growth (TTM)−168%–
Profitability
Gross margin78.6% (better)16.4%
Operating margin−56.6% (better)−80.5%
Net margin−59.9%–
FCF margin–−40.6%
Financial health
Interest coverage−10.7×−2.8× (better)
Current ratio2.33 (better)2.16
Altman Z-score−5.91–
Piotroski F-score6–
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions71.2%2.2%
Held by insiders9.2%11.0%
Superinvestors holding1–
Short interest, % of float30.9%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.